Founded in New York City during the initial COVID-19 outbreak, Kantaro Biosciences (“Kantaro”) is a joint venture between Mount Sinai and RenalytixAI, to drive rapid innovation and scale-up of rigorous, results-driven and reproducible diagnostic tests for critical health challenges. Kantaro’s groundbreaking antibody test, based on technology developed at Mount Sinai and manufactured in partnership with Bio-Techne, is the one of the first tests capable of identifying the level of an individual’s neutralizing antibodies.
Antibody Test Kits
Kantaro’s SARS-CoV-2 IgG Antibody Test Kits
Accurate
The technology underlying the diagnostic testing kits was created by an internationally recognized virology team from the Icahn School of Medicine at Mount Sinai. This technology has been translated into a commercially scalable kit by Bio-Techne recognized as a world leader in developing ELISA based tests.
Proven
The underlying technology has been performed in The Mount Sinai Hospital’s Clinical Laboratories on over 80,000 patients, used for convalescent plasma therapy decisions and to inform other clinical needs.
Accessible
The kits will be used on a simple patient blood draw and easily run by any high complexity laboratory in the world without costly proprietary equipment.
Latest News
Kantaro has only begun its journey, and there is much more to come.Please check this website for updates.
Contact Us
If you would like to provide us with your information, or have a question regarding test kits, please fill out the Intake Form.
If you would prefer to reach us by phone, please call Bio-Techne: 1-800-343-7475 (toll-free)